Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
We treated a 23-year-old aboriginal woman with drug-resistant pulmonary tuberculosis (TB). She experienced intolerance to her oral anti-TB medications, had subtherapeutic drug levels, and failed to respond to treatment. She then was effectively treated with percutaneous gastrojejunostomy tube (PGJT) administration of drugs. We present our data on the serum drug levels of rifampin, para-aminosalicylic acid, and levofloxacin after PGJT administration, and compare these values to published levels for oral administration of these drugs. In our patient, serum drug levels peaked and began to decline earlier than in the published data for oral administration of the same drugs.
Reid
John
J
Division of TB Control, Royal University Hospital, U of S Research Center for the Elimination of Tuberculosis, Saskatoon, Saskatchewan, Canada.
Marciniuk
Darcy
D
Peloquin
Charles A
CA
Hoeppner
Vernon
V
D000328:Adult; D010131:Aminosalicylic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D005774:Gastrostomy; D006801:Humans; D007582:Jejunostomy; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics; D012293:Rifampin / Q000008:administration & dosage / Q000493:pharmacokinetics; D012525:Saskatchewan; D018088:Tuberculosis, Multidrug-Resistant / Q000097:blood / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy*
D000995:Antitubercular Agents; D010131:Aminosalicylic Acid; D064704:Levofloxacin; D015242:Ofloxacin; D012293:Rifampin